Brought to you by 
Mylan gets Humira-related IP from AbbVie
09 Nov 2021
Executive Summary
AbbVie Inc. licensed Mylan NV non-exclusive rights to patents and intellectual property relating to Humira (adalimumab) in the US and certain other countries (excluding Europe) where AbbVie has IP, which Mylan will use in its development of its Hulio, a Humira biosimilar.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mylan gets Humira-related IP from AbbVie
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice